Krystal Biotech (KRYS)

Executive Summary

Krystal Biotech is a commercial-stage gene therapy company leveraging its proprietary HSV-1 platform to develop transformative treatments for genetic and rare diseases. Its first approved product, Vyjuvek (beremagene geperpavec), is a topical gene therapy for dystrophic epidermolysis bullosa (DEB), providing a strong commercial foundation. The pipeline extends into dermatology (KB301 for skin aesthetics, KB105 for ichthyosis), ophthalmology (KB801 for neurotrophic keratitis), respiratory diseases (KB407 for cystic fibrosis, KB408 for alpha-1 antitrypsin deficiency), and oncology (KB707 for melanoma). Key near-term value drivers include Phase 3 data for KB803 in DEB, which targets a broader patient population than Vyjuvek, and Phase 1 data for KB407 in cystic fibrosis. With a robust balance sheet and a validated platform, Krystal is positioned for sustained growth across multiple indications.

Upcoming Catalysts (preview)

• Q4 2026KB803 Phase 3 Top-Line Data for Dystrophic Epidermolysis Bullosa75% success
• Q2 2026KB407 Phase 1 Data Readout for Cystic Fibrosis60% success
• Q4 2026KB408 Phase 1 Interim Data for Alpha-1 Antitrypsin Deficiency50% success